Chao Wang

Chief Commercial Officer at Jona

Chao Wang is an accomplished executive with extensive experience in various leadership roles across multiple industries. Currently serving as Chief Commercial Officer at Jona, Chao is dedicated to advancing microbiome science and its implications for health. As a Venture Partner at de Anda Capital, Chao engages actively with management teams to create value through strategic investments. A member of the exclusive Operators Guild, Chao supports tech companies in scaling operations. Previous experience includes co-founding and leading Dopple, an innovative children's clothing subscription service, and heading business operations at Parsley Health. Chao's background also includes key roles at Zesty Inc. and multiple communications firms. Chao holds a BSBA in Finance and Economics from the Questrom School of Business, Boston University, and has studied History and Politics at the University of Oxford.

Location

New York, United States

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices


Jona

Jona is on a mission to reveal the relationship between our gut microbiome and health. Microbiome science has been exploding over the last decade with thousands of scientific studies showing the link to human health including GI conditions, autoimmune conditions, oncology, metabolic disease, athletic performance, longevity, depression, anxiety, Parkinson’s Disease and more. Yet, so far the microbiome has been too complex and the science too fast moving to benefit patients in practice. Jona has developed transformative AI technology to analyze an individual's microbiome, interpret the results, and summarize what is known today about that individual's microbiome profile based on the scientific literature. With actionable insights and recommendations, individual's can get to the root source of understanding their health, alleviate symptoms, and prevent chronic disease. We believe that fully realizing the microbiome in medicine will create whole new diagnostics, change patient pathways, develop new therapeutic classes, alter our food supply, and extend human longevity.


Employees

1-10

Links